Regression of ovarian cancer xenografts by depleting or inhibiting RLIP.

Abstract

Ovarian cancer (OC) is the most prevalent and deadly cancer of the female reproductive system. Women will continue to be impacted by OC-related morbidity and mortality. Despite the fact that chemotherapy with cisplatin is the main component as the first-line anticancer treatment for OC, chemoresistance and unfavorable side effects are important obstacles to effective treatment. Targets for effective cancer therapy are required for cancer cells but not for non-malignant cells because they are expressed differently in cancer cells compared to normal cells. Targets for cancer therapy should preferably be components that already exist in biochemical and signalling frameworks and that significantly contribute to the development of cancer or regulate the response to therapy. RLIP is an important mercapturic acid pathway transporter that is crucial for survival and therapy resistance in cancers, therefore, we examined the role of RLIP in regulating essential signalling proteins involved in relaying the inputs from upstream survival pathways and mechanisms contributing to chemo-radiotherapy resistance in OC. The findings of our research offer insight into a novel anticancer effect of RLIP depletion/inhibition on OC and might open up new therapeutic avenues for OC therapy.

• Authors: Sravani K Ramisetty, Pankaj Garg, Atish Mohanty, Tamara Mirzapoiazova, Er Yue, Edward Wang, David Horne, Sanjay Awasthi, Prakash Kulkarni, Ravi Salgia, Sharad S Singhal
• Journal: Biochemical pharmacology (Biochem Pharmacol) Vol. 217 Pg. 115847 (11 2023) ISSN: 1873-2968 [Electronic] England
• PMID: 37804871 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural, Research Support, U.S. Gov't, Non-P.H.S.)
• Copyright: Copyright © 2023 Elsevier Inc. All rights reserved.

Chemical References

• Cisplatin

Topics

• Humans
• Female
• Heterografts
• Ovarian Neoplasms (drug therapy, pathology)
• Signal Transduction
• Cisplatin (pharmacology, therapeutic use)
• Cell Line, Tumor
• Drug Resistance, Neoplasm